An artificial intelligence-powered solution for heart failure developed at Rochester, Minn.-based Mayo Clinic has received FDA clearance.
The EchoGo Heart Failure tool was created by Ultromics, a spinoff of the University of Oxford in the U.K. in collaboration with Mayo Clinic. It uses AI to detect heart failure with reduced ejection fraction, or HFpEF, from a single electrocardiogram image, aiming to expedite care.
"HFpEF currently is associated with high rates of hospitalization and mortality," Patricia Pellikka, MD, vice chair of cardiovascular medicine at Mayo Clinic, said in a Dec. 6 Ultromics news release. "By facilitating early diagnosis and treatment, we can improve the lives of many."